The Vote Did Not Resolve the Chemistry
On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend inclusion of the BPC-157-related bulk drug substances under consideration: BPC-157 free base and BPC-157 acetate. The recommendation was notable, but it was also narrow. An advisory committee vote is nonbinding. It does not add either substance to the 503A Bulks List, approve BPC-157 as a drug, or establish that products containing it are safe or effective.
The vote also did not resolve one of the central problems identified during FDA’s review: materials sold or described as “BPC-157” are not always defined consistently.
FDA evaluated more than whether BPC-157 might work. Its review addressed physical and chemical characterization, historical use in compounding, evidence of effectiveness, safety, immunogenicity, and the availability of approved alternatives. On the chemistry side, FDA found inconsistent naming, conflicting information about which bulk drug substance had actually been nominated, and inadequate data for several critical quality attributes.
That distinction matters. The problem is not that a synthetic BPC-157 peptide is impossible to define. The problem is that the name alone does not adequately define the material in a vial.
What Can Be Defined
The amino-acid sequence generally associated with BPC-157 is:
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Using the one-letter amino-acid code, the sequence is:
GEPPPGKPADDAGLV
The free peptide, which FDA refers to as BPC-157 free base, has the molecular formula C₆₂H₉₈N₁₆O₂₂ and an average molecular weight of approximately 1419.5 g/mol. Its calculated neutral monoisotopic mass is approximately 1418.7042 Da.
BPC-157 is commonly described in the literature as a synthetic version of a 15-amino-acid fragment associated with a larger “body protection compound” reportedly derived from human gastric juice. Questions surrounding the complete parent protein and the claimed natural origin are scientifically relevant, but they should not be confused with the analytical identity of a synthetic peptide.
A laboratory can determine whether a material is consistent with the expected GEPPPGKPADDAGLV sequence. Establishing that chemical identity does not independently prove the peptide’s claimed biological origin, pharmacological activity, safety, or effectiveness.
There is no applicable USP or National Formulary monograph for either BPC-157 free base or BPC-157 acetate, and neither is a component of an FDA-approved drug. There is therefore no compendial monograph that establishes a standardized collection of identity tests, assay procedures, impurity limits, counterion requirements, and other acceptance criteria.
That does not prevent competent analytical testing. It does mean that the specification must be scientifically justified rather than copied from a monograph that does not exist.
The Sequence Is Not the Entire Substance
A peptide name and sequence are only the beginning of a material specification.
FDA’s review found that the nomination packages did not consistently identify whether the substance under consideration was BPC-157 free base or BPC-157 acetate. Information such as the UNII code, CAS number, molecular formula, and molecular weight corresponded to the free peptide, while the submitted certificates of analysis described the material as BPC-157 acetate.
That is not a minor documentation problem. A certificate of analysis should describe the substance that was actually tested. It should not use the identifiers for one form while reporting another.
FDA also identified missing or inadequate information concerning peptide-related impurities, aggregates, microbial quality, bacterial endotoxins, residual solvents, particle size, and other attributes that could become relevant depending on the dosage form and route of administration.
The scientifically defensible question is therefore not simply:
Is the sequence GEPPPGKPADDAGLV present?
The complete question is:
Is the material adequately characterized with respect to peptide identity, counterion composition, peptide content, purity, related substances, aggregates, residual processing materials, water content, and any other quality attributes relevant to its intended use?
A product can contain the correct sequence and still be inaccurately labeled, underfilled, contaminated, degraded, or composed largely of water, counterions, residual solvents, and other nonpeptide material.
Why “Free Base” and “Acetate” Cannot Be Treated as Interchangeable
FDA evaluated BPC-157 free base and BPC-157 acetate as distinct bulk drug substances. The peptide moiety may be the same, but the complete materials are not analytically identical.
For BPC-157 free base, FDA listed the formula as C₆₂H₉₈N₁₆O₂₂ and the average molecular weight as approximately 1419.5 g/mol.
For BPC-157 acetate, FDA used the formula:
C₆₂H₉₈N₁₆O₂₂·x(C₂H₄O₂)
The variable x is important. It indicates that FDA did not assign a fixed acetate stoichiometry or a single molecular weight to all material described as BPC-157 acetate.
A theoretical material containing exactly one equivalent of acetic acid per peptide molecule would have an average formula weight of approximately 1479.6 g/mol. That value should not be presented as the universal molecular weight of “BPC-157 acetate” unless a 1:1 composition has actually been established.
The presence and amount of counterions also affect mass balance. A vial containing 10 mg of lyophilized powder does not necessarily contain 10 mg of BPC-157 peptide. The powder may also contain acetate, trifluoroacetate, chloride, water, residual solvents, excipients, and synthesis-related impurities.
This is why gross powder weight, chromatographic purity, and peptide content are different measurements.
Counterion composition may also influence solid-state behavior, solution pH, solubility, chromatographic behavior, and stability. Those effects must be demonstrated for the actual material and formulation. They should not be assumed solely because the supplier used the word “acetate.”
What the Available Analytical Methods Actually Tell Us
No single test establishes every relevant attribute of a peptide. A defensible characterization program uses orthogonal methods, with each method answering a specific question.
High-Resolution Intact-Mass Spectrometry
High-resolution mass spectrometry measures the mass-to-charge ratios of peptide ions. From those measurements, the laboratory can calculate a neutral monoisotopic mass and determine whether the observed peptide is consistent with the expected elemental composition.
For BPC-157, an intact-mass result consistent with the calculated mass provides strong evidence that the sample contains a peptide with the expected overall molecular composition. It can readily reveal gross synthesis errors, major truncations, certain substitutions, chemical modifications, or incorrect labeling.
It does not, by itself, prove the complete amino-acid sequence. Different sequences or structures can have the same nominal or exact mass.
Intact mass also does not normally establish acetate stoichiometry. Under common electrospray ionization conditions, the instrument generally detects protonated or multiply protonated ions of the peptide moiety. Noncovalently associated counterions may dissociate during ionization. The absence of an acetate-associated peptide ion is therefore not evidence that acetate is absent from the original powder.
LC-HRMS/MS Sequence Confirmation
Tandem mass spectrometry fragments the peptide and compares the resulting product ions with fragments predicted from the expected sequence.
LC-HRMS/MS can provide strong confirmation of the GEPPPGKPADDAGLV primary structure when sufficient diagnostic fragment-ion coverage is obtained. It can also help identify many truncations, deletion sequences, substitutions, and modified forms.
The result must still be interpreted correctly. Confidence depends on chromatographic separation, spectral quality, fragmentation coverage, mass accuracy, and the suitability of the data-processing criteria. MS/MS does not automatically distinguish every isomeric substitution, and it does not prove that no sequence-related impurities are present elsewhere in the chromatogram.
FDA’s work on peptide products similarly emphasizes the use of LC-HRMS and other advanced methods to characterize both target peptides and structurally related impurities.
Counterion Analysis
Ion chromatography can identify and quantify anions such as acetate, trifluoroacetate, chloride, and formate.
This is essential when a material is labeled as an acetate salt or when trifluoroacetate may remain from peptide cleavage and purification. Counterion testing can determine what anions are present and how much of each is present. Ion chromatography is commonly used for quantitative analysis of peptide-associated counterions.
Counterion analysis alone does not prove that all detected acetate is stoichiometrically associated with the peptide. Acetate could also be present as a processing residual, buffer component, or excipient. Estimating counterion-to-peptide stoichiometry requires both a quantitative counterion result and an independently determined peptide content.
Reversed-Phase HPLC-UV Purity
Reversed-phase HPLC-UV separates the principal peptide peak from many process-related and degradation-related components. It provides a chromatographic related-substances profile and can determine whether the target peptide is the predominant UV-absorbing species in the sample.
A reported result such as “99.2% purity” is usually an area-percent calculation:
Area of the principal peak ÷ total integrated peak area × 100
That is chromatographic purity. It is not automatically equivalent to peptide assay, mass purity, or the percentage of the vial that consists of BPC-157.
Several limitations must be considered:
- Impurities can coelute with the principal peak.
- Different compounds can have different UV response factors.
- Non-UV-absorbing materials may not be included in the calculation.
- Water, salts, and many residual components are not represented by peptide peak-area percentage.
- HPLC-UV alone usually does not identify the chemical structure of an impurity peak.
A purity result must therefore be interpreted as one part of the analytical package, not as proof of identity and quantity by itself.
Amino Acid Analysis
Amino acid analysis hydrolyzes the peptide and quantitates the resulting amino acids. It can provide an independent assessment of amino-acid composition and, when properly calibrated and corrected for hydrolysis behavior, can support absolute peptide-content determination.
AAA does not establish sequence order because hydrolysis destroys the original peptide chain. Two peptides with different sequences can have the same amino-acid composition.
Its value is orthogonality. It examines the material through different chemistry than intact mass, MS/MS, or HPLC-UV.
Aggregate and Additional Quality Testing
Peptides may form dimers, oligomers, or larger aggregates during manufacture, formulation, or storage. Reversed-phase HPLC does not necessarily provide adequate aggregate detection. Size-exclusion chromatography, field-flow fractionation, light-scattering techniques, or other suitable methods may be required depending on the product and risk. FDA specifically identified aggregation and peptide-related impurities as relevant concerns in its BPC-157 evaluation.
A complete specification may also require testing for:
- Peptide content or assay
- Water content
- Residual solvents
- Residual synthesis reagents
- Specified and unspecified related substances
- Elemental impurities
- Bioburden
- Bacterial endotoxins
- Sterility
- Particulate matter
- pH after reconstitution
- Fill quantity and content uniformity
- Stability-indicating changes over time
The appropriate tests depend on whether the sample is a bulk drug substance, a nonsterile formulation, or a finished sterile preparation.
Identity is necessary. It is not the entire quality system.
The Real-World Quality Gap
The distinction between identity, purity, and quantity is not academic.
NBC Washington reported that a laboratory involved in independent peptide testing said nearly 30% of the samples submitted to it showed one or more problems, including labeling discrepancies, dose discrepancies, toxins, or evidence of microbial contamination. That figure should be interpreted cautiously. The samples were not described as a randomized or representative survey of the entire peptide market, and the public report did not provide a complete analytical breakdown for every sample. It should not be presented as the universal failure rate for peptide products.
The broader conclusion remains valid: products carrying the same peptide name can differ substantially in identity, purity, content, counterions, and microbial quality.
The lack of harmonized specifications does not itself cause contamination, underfilling, or manufacturing errors. Those failures arise from inadequate manufacturing controls, formulation errors, poor aseptic processing, deficient supplier qualification, or weak quality systems.
What incomplete specifications do is make those failures harder to detect and easier to obscure.
A certificate of analysis can report “BPC-157, 99% purity” while leaving unanswered:
- Was the sequence confirmed?
- Was the reported mass the average molecular weight or an observed mass-spectrometric ion?
- Was the material free peptide, acetate, trifluoroacetate, chloride, or a mixture?
- Was the 99% result chromatographic area percentage or actual peptide content?
- How much peptide was present in the vial?
- Were related impurities identified?
- Were aggregates evaluated?
- Was the material tested for water or residual solvents?
- Were endotoxins, bioburden, sterility, and particulate matter assessed where relevant?
Without those details, a high purity number can create more confidence than the data justify.
What the PCAC Vote Means
The PCAC recommendation is advisory. FDA is not legally bound to follow it, and the committee vote did not itself place BPC-157 free base or BPC-157 acetate on the 503A Bulks List.
Under section 503A, a bulk drug substance generally must comply with an applicable USP or NF monograph, be a component of an FDA-approved drug when no applicable monograph exists, or appear on the 503A Bulks List. BPC-157 currently lacks a relevant drug-substance monograph and is not a component of an FDA-approved drug. Further FDA action would therefore be required before the committee’s recommendation changes the substance’s status under the 503A framework.
Even if FDA ultimately adds one or both forms to the list, that would not constitute FDA approval of BPC-157. It would not establish clinical safety or effectiveness, and it would not approve a particular formulation, route of administration, dose, or therapeutic claim.
Compounders would still be responsible for supplier qualification, appropriate specifications, valid certificates of analysis, suitable analytical procedures, formulation controls, release testing, and compliance with all other applicable requirements.
The vote may change the regulatory path. It does not lower the analytical burden.
What a Useful BPC-157 Certificate of Analysis Should Establish
The exact specification will depend on the material and intended use, but a scientifically meaningful certificate of analysis should clearly address the following:
Substance definition: The report should identify the material actually tested, including whether it is being represented as free peptide, acetate, trifluoroacetate, chloride, or another form.
Expected sequence: The report should state the sequence and terminal configuration being evaluated.
Identity method: The certificate should identify the method used, such as intact LC-HRMS, LC-HRMS/MS sequence confirmation, comparison with a qualified reference material, or an appropriately justified combination of methods.
Mass terminology: The certificate should distinguish among average molecular weight, calculated monoisotopic mass, and observed mass-to-charge ratio. These values are related, but they are not interchangeable.
Chromatographic purity: The method, detection conditions, integration approach, and result should be stated. Area-percent purity should not be mislabeled as peptide content.
Peptide content or assay: The report should establish how much BPC-157 peptide is present on a clearly defined basis, such as as-is, dried, anhydrous, or counterion-corrected.
Counterion composition: The identity and amount of acetate, trifluoroacetate, chloride, or other relevant ions should be reported when the salt designation or mass balance depends on them.
Related substances and aggregates: Meaningful controls should be established for relevant peptide-related impurities, synthesis-related materials, degradation products, and aggregates.
Additional quality attributes: Water, residual solvents, bioburden, endotoxins, sterility, particulate matter, and other attributes should be included when relevant to the material’s intended use.
A certificate that only says “BPC-157, 99%” does not adequately characterize the substance.
What This Means for Clinics, Pharmacies, and Individuals
Clinics evaluating compounded peptide products should ask the pharmacy how the bulk material was qualified. The questions should include the exact form, the identity method, the assay basis, the counterion result, the impurity profile, and the testing performed on the finished preparation.
Compounding pharmacies should not rely solely on a supplier’s product name or a generic HPLC chromatogram. Supplier qualification and incoming-material specifications should address the actual chemical and microbiological risks presented by the substance and intended dosage form.
Individuals should understand that a label is a claim. A certificate of analysis is only as useful as the methods, specifications, sample traceability, and quality system behind it.
The Answer Comes From Data, but Not From One Instrument
The expected synthetic BPC-157 sequence can be defined and analytically characterized. The real identity problem is that products sold under the same name may not be consistently specified with respect to form, counterions, peptide content, purity, related substances, aggregates, or other critical quality attributes.
Analytical testing can determine whether a material is consistent with the expected sequence. It can measure peptide content, characterize counterions, assess chromatographic purity, and investigate relevant impurities.
It cannot, by itself, establish that BPC-157 is clinically safe or effective. It cannot confirm a disputed biological origin. It cannot turn an advisory committee recommendation into FDA approval.
What analytical chemistry can do is force the discussion to begin with a defined substance instead of a name printed on a label.
That is where any credible evaluation of BPC-157 has to start.
Vanguard Laboratory is an ISO 17025 accredited peptide testing facility. We provide identity, purity, and safety testing for clinics, compounding pharmacies, and individuals. Learn more at vanguardlaboratory.com.
References
[1] Forbes. “FDA’s Review Of Peptides Signals A Growing Public Health Challenge — Separating Science From Hype.” July 21, 2026.
[2] The FDA Law Blog. “PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List.” July 24, 2026.
[3] Forbes. “FDA’s Review Of Peptides Signals A Growing Public Health Challenge.” July 21, 2026.
[4] Velox Peptides. “FDA Panel Votes to Recommend 6 of 7 Peptides for Compounding, Rejects DSIP.” July 25, 2026.
[5] Cre8tive Labs. “The FDA Briefing Documents Are In: What Researchers Need to Know About the July 23-24 PCAC Hearing.” July 22, 2026.
[6] NBC Washington. “Peptides: Lab finds problems in 30% of vials tested as FDA panel eyes loosening rules.” July 23, 2026.
[7] LA Times. “Buying Peptides Online? Here’s How to Spot Fake and Dangerous Products.” July 24, 2026.